top of page

Mock FDA/EMA Inspections and Inspection Readiness

Why mock inspections belong in a readiness plan

A regulatory inspection is not the moment to discover that batch records are inconsistent, that a CAPA did not actually prevent recurrence, or that staff cannot explain a process the way the SOP describes it. Mock FDA and EMA inspections exist to find those gaps while you can still fix them.

GxP Auditing & Consulting Services provides inspection-readiness support and mock inspections led by Ramzi W. Kozal, CQA, an independent GxP lead auditor with nearly 30 years of experience and about 245 audits logged. After mock inspections, the practice has a record of zero critical observations. That record is a statement about the mock inspection work itself. It is not a promise about how a future agency inspection will end.

Readiness work is useful when a pre-approval inspection is reasonably foreseeable, when a surveillance inspection window is open, when a prior inspection left unfinished work, or when a new product, facility, or quality system has not yet been tested under inspection conditions.

What a mock FDA or EMA inspection includes
A mock inspection is scoped to resemble the way a real investigator works, not a casual facility tour. The exact agenda depends on the operation, but the work typically includes:
• A focused review of the quality system, including deviation management, CAPA effectiveness, change control, training, and document control
• Sampling of batch records, laboratory records, or clinical and supplier files that an investigator would be likely to request
• A facility or process walk-through when the scope is on site, including areas such as aseptic processing, radiopharmaceutical operations, or QC laboratories
• Interviews that test whether staff can explain their work consistently with procedures and records
• A closeout discussion and a written report with findings ranked by risk, plus practical recommendations

For pharmaceutical manufacturers, CMOs, and CDMOs, the regulatory frame is often 21 CFR Parts 210 and 211. For radiopharmaceutical and PET drug operations, readiness is built around 21 CFR Part 212, including short half-life constraints, containment, and radiation safety expectations. Medical device programs may be assessed against 21 CFR Part 820, ISO 13485, and notified body or FDA inspection practice. Dietary supplement operations may be reviewed under 21 CFR Part 111.

Where computerized systems and electronic records are part of the story, 21 CFR Part 11 and data integrity expectations are included in the readiness review rather than treated as a side topic.

Who this service is for
Inspection readiness is for companies that already have a quality system and need to know whether it will hold up. That includes pharmaceutical and biotech manufacturers, radiopharmaceutical and PET facilities, medical device companies, dietary supplement manufacturers, and sponsors that need to be ready for questions about their vendors as well as their own sites.

It is also a fit for organizations preparing for EMA as well as FDA attention, or for a program that must satisfy more than one authority. The mock inspection can be tailored to the agency and the product type, instead of using a generic "inspection prep" script.

How readiness work is planned
The first step is to define the plausible inspection scope: product, process, facility, quality system, and whether the likely inspection is pre-approval, for-cause, or routine. From there, document requests, interview lists, and walk-through paths are set so the exercise uses your time well.

Work may be fully remote, on site, or a combination. Remote work can still be rigorous when records, interviews, and system access are organized in advance. On-site work is often the better choice when facility flow, gowning, or shop-floor practice will be part of the inspection.

Findings are discussed in plain language. The goal is not to produce a long list of minor observations with no sense of priority. Critical, major, and minor issues are separated so leadership can put effort where it reduces inspection risk first.

After the mock inspection
A mock inspection is only useful if the organization acts on it. Support can continue into CAPA planning, procedure revisions, training, and a follow-up check of whether the original findings were actually closed. If a later FDA 483 or warning letter response is needed, that work can be part of the same engagement.

Companies that want a broader quality system overhaul, vendor requalification, or a data integrity and computer system validation review can extend the same engagement rather than starting from zero with a new provider.

Work with a CQA lead auditor
Inspection readiness at this practice is led by the principal auditor, not handed off after the sales call. Ramzi brings direct experience in pharmaceuticals, radiopharmaceuticals, cell and gene therapy, mRNA and LNP platforms, and dietary supplements, along with CQA credentials and a large logged audit volume.

If an inspection is on the calendar, or you want to know whether you would be ready if it were, contact GxP Auditing & Consulting Services to scope a mock FDA or EMA inspection. Call (239) 207-8132 or use the contact page to schedule a consultation.

Frequently Asked Questions

How is a mock inspection different from a routine internal audit?
A routine internal audit often follows a planned checklist against your own procedures. A mock FDA or EMA inspection is designed to resemble how an investigator samples records, interviews staff, and traces issues from the shop floor or the quality system. The tone, the evidence trail, and the report are built around inspection readiness, not only SOP compliance.

Can a mock inspection be done remotely?
Yes. Many readiness reviews can be performed remotely when records and interviews can be organized in advance. On-site work is recommended when facility practice, material flow, or aseptic and radiopharma operations will be a central inspection topic.

What does "zero critical observations after mock inspections" mean?
It means that after mock inspections led through this practice, there have been no critical observations in those exercises. It is not a guarantee that a future FDA or EMA inspection will have the same result.

How long does readiness support take?
Timing depends on the size of the operation and the scope. A focused mock inspection of

a defined process or quality system can often be planned in days, while a broader multi-

system readiness program takes longer. Scope and timing are set during the consultation.

Do you also help after a real inspection?
Yes. Support is available for CAPA follow-up and for FDA 483 or warning letter response work, including quality system remediation in platforms such as Veeva Vault and TrackWise.​

bottom of page